Literature DB >> 21789160

Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists.

Jorge A Garcia1.   

Abstract

Sipuleucel-T represents a novel immunotherapeutic compound designed to stimulate an immune response against castration-resistant prostate cancer (CRPC). Sipuleucel-T is an autologous active cellular immunotherapy product, which includes autologous dendritic cells pulsed ex vivo with PAP2024, a recombinant fusion protein made of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor. Despite the lack of prostate-specific antigen and objective response, a recent phase III randomized trial demonstrated a significant improvement in overall survival in asymptomatic and minimally symptomatic CRPC patients. This review summarizes the clinical development of Sipuleucel-T in CRPC that led to the regulatory approval of this compound in the USA.

Entities:  

Keywords:  Sipuleucel-T; castrate-resistant prostate cancer; immunotherapy; vaccine

Year:  2011        PMID： 21789160      PMCID： PMC3126040          DOI： 10.1177/1758834010397692

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  24 in total

1.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

Authors:  E J Small; P Fratesi; D M Reese; G Strang; R Laus; M V Peshwa; F H Valone
Journal:  J Clin Oncol       Date:  2000-12-01       Impact factor: 44.544

Review 2.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).

Authors:  G J Lieschke; A W Burgess
Journal:  N Engl J Med       Date:  1992-07-02       Impact factor: 91.245

3.  Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer.

Authors:  Daniel R Rhodes; Terrence R Barrette; Mark A Rubin; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

4.  Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

Authors:  Brian I Rini; Vivian Weinberg; Lawrence Fong; Shauna Conry; Robert M Hershberg; Eric J Small
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

5.  Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

Authors:  Garth Beinart; Brian I Rini; Vivian Weinberg; Eric J Small
Journal:  Clin Prostate Cancer       Date:  2005-06

Review 6.  Control of prostate growth.

Authors:  D S Coffey; J T Isaacs
Journal:  Urology       Date:  1981-03       Impact factor: 2.649

7.  Autoantibody signatures in prostate cancer.

Authors:  Xiaoju Wang; Jianjun Yu; Arun Sreekumar; Sooryanarayana Varambally; Ronglai Shen; Donald Giacherio; Rohit Mehra; James E Montie; Kenneth J Pienta; Martin G Sanda; Philip W Kantoff; Mark A Rubin; John T Wei; Debashis Ghosh; Arul M Chinnaiyan
Journal:  N Engl J Med       Date:  2005-09-22       Impact factor: 91.245

8.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

9.  Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Authors:  Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

10.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544
View more
  4 in total

Review 1.  Science gone translational: the OX40 agonist story.

Authors:  Andrew D Weinberg; Nicholas P Morris; Magdalena Kovacsovics-Bankowski; Walter J Urba; Brendan D Curti
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 2.  Human prostatic acid phosphatase: structure, function and regulation.

Authors:  Sakthivel Muniyan; Nagendra K Chaturvedi; Jennifer G Dwyer; Chad A Lagrange; William G Chaney; Ming-Fong Lin
Journal:  Int J Mol Sci       Date:  2013-05-21       Impact factor: 5.923

Review 3.  Emerging roles of human prostatic Acid phosphatase.

Authors:  Hoon Young Kong; Jonghoe Byun
Journal:  Biomol Ther (Seoul)       Date:  2013-01       Impact factor: 4.634

Review 4.  Advances in Engineering Cells for Cancer Immunotherapy.

Authors:  Xiao Xu; Teng Li; Shiyang Shen; Jinqiang Wang; Peter Abdou; Zhen Gu; Ran Mo
Journal:  Theranostics       Date:  2019-10-16       Impact factor: 11.556
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.